Welcome to our dedicated page for Modular Med news (Ticker: MODD), a resource for investors and traders seeking the latest updates and insights on Modular Med stock.
Modular Medical Inc (NASDAQ: MODD) delivers innovative insulin pump technology designed to transform diabetes care. This news hub provides investors and healthcare professionals with essential updates on the company's progress in medical device development, regulatory milestones, and strategic partnerships.
Access timely information about MODD's patented diabetes management solutions, including FDA clearances, manufacturing expansions, and clinical advancements. Our curated news collection helps stakeholders track developments in user-friendly insulin delivery systems and the company's mission to expand access to affordable diabetes technology.
Key updates include product innovation timelines, regulatory submissions, intellectual property developments, and partnership announcements. Bookmark this page for consolidated access to MODD's latest achievements in medical device engineering and diabetes care solutions.
Modular Medical (NASDAQ:MODD) has announced a proof-of-concept study with Gubra A/S to explore the potential use of its MODD1 pump platform for delivering short-acting peptides as an alternative for patients who discontinue long-acting GLP-1 formulations. The study will use a high-fat, diet-induced obese (DIO) mouse model to determine if an FDA-approved, short-acting peptide delivered via pump can provide comparable glycemic control and weight loss with improved tolerability for people with type 2 diabetes and obesity.
This research aims to address the high discontinuation rates of GLP-1 drugs due to tolerability issues, cost, and inconsistent efficacy. Modular Medical believes that pump technology could simplify and improve dosing regimens for short-acting peptides, potentially offering a more personalized and tolerable solution for patients who struggle with long-acting GLP-1 therapies.
Modular Medical (NASDAQ: MODD), a company focused on developing user-friendly and affordable insulin pump technology, has announced its addition to the Russell Microcap Index. This inclusion will take effect on July 1, 2024, following the annual reconstitution of the Russell indexes.
Membership in the Russell Microcap Index will last for one year, providing Modular Medical automatic inclusion in various growth and value style indexes. FTSE Russell, which oversees this inclusion process, determines membership based on objective market-capitalization rankings and style attributes. The Russell indexes are widely utilized by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against these U.S. indexes.
This development could enhance Modular Medical's visibility and attract more investors.
Modular Medical (NASDAQ: MODD), a development-stage company focused on innovative insulin delivery technologies, announced its participation in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The conference will be held virtually, and the company will deliver a webcasted presentation at 3:30 p.m. ET. CEO Jeb Besser will also host one-on-one meetings with investors. The webcast can be accessed through the conference home page and will be available for replay.
FAQ
What is the current stock price of Modular Med (MODD)?
What is the market cap of Modular Med (MODD)?
